Dose Escalation Data from transcendIT-101 Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors Presented
“We are very pleased to see intratumoral TransCon TLR7/8 Agonist administration working as designed to deliver prolonged, high local concentrations of resiquimod, steadily activating and intensifying the body’s innate and adaptive immune responses over weeks with a single injection,” said Stina Singel, Senior Vice President, Head of Clinical Development, Oncology at Ascendis Pharma. “With these early signs of clinical activity, including monotherapy abscopal activity, and no signs of systemic toxicity, we look forward to continuing our work with investigators and patients to further assess TransCon TLR7/8 Agonist’s ability to promote potent anti-tumoral responses while minimizing toxic systemic exposures.”
Share:
More News
“From the outset, our goal has been to build a discovery engine that systematically unlocks high-value, challenging targets and delivers first-in-class precision medicines,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares. “This collaboration lets us scale that engine alongside Novartis’ world-class development capabilities and global reach, so we
“We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer,”
“VS-7375 has demonstrated anti-tumor activity across multiple dose levels and tumor types, encouraging signals from rational combination strategies, and a favorable safety profile that improves meaningfully beyond the first treatment cycle, underscoring its potential to be not only the best-in-class oral KRAS G12D inhibitor, but also the preferred treatment option
“We are pleased that the FDA has demonstrated urgency in reconsidering the RP1 BLA with an expeditious action date in recognition of the significant unmet need for advanced melanoma patients and support from the broader melanoma community,” said Sushil Patel, Ph.D., CEO of Replimune. “We look forward to a productive